Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Finding Study of Bryostatin-1 and GM-CSF in Refractory Myeloid Malignancies

NCT00012376 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00012376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00012376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Finding Study of Bryostatin-1 and GM-CSF in Refractory Myeloid Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2001
Completion date
Not reported
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), blastic phase chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic phase chronic myelogenous leukemia, paroxysmal nocturnal hemoglobinuria, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, refractory anemia, refractory anemia with ringed sideroblasts, relapsing chronic myelogenous leukemia, thrombocytopenia, untreated adult acute myeloid leukemia